Drug Profile
Felbinac intravenous - Guangdong Zhongke Drug Research & Development/Shijiazhuang Yiling Pharmaceutical
Alternative Names: 4-Biphenylacetic acid; 4-Biphenylacetic Acid Trishydroxymettiylaminometnane; BPAA; CL-83544; Felbinac intravenous; Felbinac trometamolLatest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Shijiazhuang Yiling Pharmaceutical
- Class Nonsteroidal anti-inflammatories; Phenylacetates
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
- No development reported Inflammation
Most Recent Events
- 28 Sep 2022 Felbinac intravenous is still in phase III trials for Postoperative pain in China (IV) (NCT05297669)
- 30 Jun 2022 Shijiazhuang Yiling Pharmaceutical completes a phase III trial in Postoperative pain in China (IV) (NCT05297669)
- 30 Jun 2022 Shijiazhuang Yiling Pharmaceutical completes a phase-III clinical trial in Postoperative pain in China (IV) (NCT04526132)